Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...
Daily1h
Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria
Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...
Daily2h
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly diagnosed multiple myeloma: Sanofi
Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...
LEADERSHIP Newspaper7h
10 Firms Close Shop Over Nigeria’s Harsh Economy In 1 Year
No fewer than 10 companies have shut down or relocated their operations from Nigeria due to the current economic challenges, ...
Outlook for Healthcare Stocks Dims With Choice of Kennedy to Lead HHS
The decision makes it impossible to guess what might come next for the healthcare industry. Robert F. Kennedy Jr. is unlike ...